MedTrace Logo

Single Dose Lipopolysaccharide (LPS) Study In Healthy Volunteers

NCT01314885 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2012-02-02

No results posted yet for this study

Summary

A single dose study with the inhaled anti-inflammatory agent PF-03715455 to establish if it has anti-inflammatory activity following a challenge with LPS. Inhaled LPS invokes an acute inflammatory response in the lung which can be seen in induced sputum. PH-0797804 is an internal control for the study.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

PF-03715455

20mg, Inhaled, single dose

DRUG

PH-797804

30mg, Oral, single dose

DRUG

Placebo for PF-03715455

Single dose, inhaled, Placebo for PF-03715455

DRUG

Placebo for PH-797804

Single Dose, Oral, Placebo for PH-797804

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01314885 on ClinicalTrials.gov